{
    "nctId": "NCT02065232",
    "briefTitle": "Sentinel Lymph Node Mapping Post-Injection Site Pain",
    "officialTitle": "A Randomized, Double-blinded, Controlled Clinical Trial Comparing Post-injection Site Pain of Technetium-labeled Tilmanocept Versus Technetium-labeled Sulfur Colloid in Patients Undergoing Sentinel Lymph Node Mapping Procedure for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Change from baseline level of discomfort",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patient has a diagnosis of biopsy-proven primary breast cancer or a diagnosis of pure ductal carcinoma in situ (DCIS) who will be undergoing intraoperative lymphatic mapping as part of their standard surgical plan.\n* The patient has provided written informed consent before participating in the study, as has his/her responsible caregiver, if applicable.\n* The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.\n* The patient is greater than 18 years of age at the time of consent.\n* The patient has an performance status of Grade 0 - 2.\n* The patient has a clinical negative node status at the time of study entry.\n* If the patients is of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of radiopharmaceutical, has been surgically sterilized, or has been postmenopausal for at least 1 year.\n\nExclusion Criteria:\n\n* The patient is pregnant or lactating.\n* The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}